ST葫芦娃（605199）(605199.SH)发布公告，公司近日收到国家药品监督管理局(简称"国家药监局")核准 签发的关于盐酸左沙丁胺醇雾化吸入溶液的《药品注册证书》。盐酸左沙丁胺醇雾化吸入溶液适用于治 疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛。 ...

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026. The lawsuit follows a series of regulatory setbacks—including an SEC subpoena and a devastating Complete Response Letter (CRL) from the FDA—that led to a sharp stock decline, with the final news t ...

U.S. stock futures are pointing to a robust start for Monday, January 5th, 2026, as markets react to significant geopolitical developments and sustained optimism in the technology sector. Premarket trading activity indicates a positive sentiment, with major indexes poised for gains as investors digest a mix of corporate news and upcoming economic data.Premarket Trading and Futures MovementsAs the first full trading week of 2026 commences, U.S. stock futures are largely in the green. S&P 500 e-mini futures a ...

New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactionsTEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its DeepSolar business unit has launched Smart TDD, an advanced solar Technical Due Diligence (“TDD”) service designed to provide faster, more accurate, and more co ...

- New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that it has entered into a Subscription Agreement (the "2025 SA") with a group of investors for the purchase and sale of an aggr ...

Shares of LifeMD (LFMD) and GoodRx (GDRX) traded higher in the premarket on Monday after the companies announced the availability of Novo Nordisk’s (NVO) Wegovy pill as part of their product offerings. The announcements came shortly after the Danish drugmaker ...

行业趋势与AI应用 - 医疗健康行业是人工智能的主要应用领域之一，AI正被用于合成新药化合物、制造更精确的测量设备以及实现更快更准确的诊断 [1] - 人工智能在2024年从根本上重塑了医疗格局，革新了诊断、治疗和运营效率，其中AI辅助诊断在提升准确性和速度方面占据了核心地位 [1] - 尽管医疗保健板块通常具有防御性，股票多呈现低贝塔和派息特征，但AI的广泛使用已使其中部分股票转变为潜在的高增长标的 [2] 礼来公司 - 公司产品线覆盖广泛治疗领域，专注于心脑血管代谢、神经科学、肿瘤学和免疫学等高增长、高商业潜力的领域 [5] - 其GLP-1药物Mounjaro和Zepbound需求强劲，是关键的营收增长动力，在新国际市场上市以及增产改善供应推动了2025年迄今的强劲销售 [6] - 其他新药如Kisunla、Omvoh和Jaypirca也贡献了营收增长，公司在肥胖和糖尿病领域研发管线进展迅速，口服GLP-1肥胖药orforglipron预计明年推出 [7] - 公司与OpenAI合作发现新药，并向利用AI模型发现RNA靶向药物的生物技术公司Genetic Leap投资了4.09亿美元 [7][9] - 公司正与英伟达合作建造制药领域最强大的超级计算机，以支持管理从数据输入、训练到微调和高通量推理的整个AI生命周期的“AI工厂” [9] - 公司当前财年预期营收和盈利增长率分别为22.3%和41.3%，过去30天当前财年盈利的共识预期上调了0.7% [9] - 公司贝塔值为0.35，当前股息收益率为0.6%，净资产收益率为109.5%，远高于行业平均的37%和标普500指数的17% [9][10] 美敦力公司 - 公司积极将AI融入其解决方案以提升患者护理和优化运营，在外科系统中，与Vizient合作推出了AI驱动的手术视频管理与分析平台 [11] - 其基于AI的内窥镜模块GI Genius是一个计算机算法辅助检测系统，能在结肠镜检查中发现医生可能遗漏的结直肠息肉模式，从而提高患者生存率 [12] - 与CathWorks的合作利用AI优化心脏手术流程，提高诊断精度和患者疗效，这将通过改善临床结果、简化工作流程来驱动公司增长 [13] - 公司正在全球扩张以满足对先进医疗器械未满足的需求，在心血管领域正获得市场份额，高血压治疗领域Symplicity的CMS覆盖带来了数十亿美元的市场机会 [14] - 公司当前财年（截至2026年4月）预期营收和盈利增长率分别为7.5%和2.7%，过去60天当前财年盈利的共识预期上调了0.4% [15] - 公司贝塔值为0.71，当前股息收益率为3%，净资产收益率为14.9%，高于行业平均的-2.5% [15] 直觉外科公司 - 公司正越来越多地将AI和数字工具嵌入其机器人生态系统，集成于da Vinci 5的Case Insights功能结合手术视频与力/运动数据，为外科医生提供客观性能指标 [16] - 这些AI驱动的洞察既为新手外科医生提供培训价值，也为专家提供实时决策支持，公司还通过Intuitive Telepresence试点远程协作，允许远程手术支持和教育 [17] - 商业推广、工作流程改变和监管调整使公司与更广泛的AI驱动医疗转型保持一致，数字和AI功能可能成为重要的差异化因素 [18] - 公司第三季度业绩强劲，营收和每股收益超预期，da Vinci 5系统在美国已安装240台，总安装基数达929台，并在欧洲和日本获准分阶段推广 [19] - 公司当前财年预期营收和盈利增长率分别为14.3%和11.1%，过去30天当前财年盈利的共识预期上调了0.4% [20] - 公司净资产收益率为15.1%，高于行业平均的-18.7% [20] 再生元制药公司 - 公司在运营中广泛使用人工智能和机器学习，主要用于药物靶点识别与验证、临床试验优化、精准医疗以及临床数据管理和分析 [21] - 公司与Viz.ai合作研究一款利用自然语言处理分析电子健康记录数据的AI工具 [21] - 尽管其主打药物Eylea销售额下降，但公司2025年营收仍实现增长，增长动力来自Eylea HD在美国的强劲表现，以及Dupixent和Libtayo的全球销售 [22] - 药物Dupixent在已获批适应症中需求增长，Libtayo在肿瘤学领域的持续标签扩展加强了其肿瘤产品组合，该组合在2025年因Lynozyfic获FDA批准而得到提振 [23] - 公司当前财年预期营收和盈利增长率分别为4.9%和-0.4%，过去30天当前财年盈利的共识预期上调了2.8% [24] - 公司贝塔值为0.39，当前股息收益率为0.5%，净资产收益率为13.8%，远高于行业平均的-65.41% [24] 强生公司 - 公司拥有重要的医疗科技部门，专注于医疗器械和诊断，并将AI技术应用于手术机器人、数字手术分析和成像领域 [25] - 公司开发了名为Ottava的AI赋能生态系统，作为其下一代机器人手术平台，并开发了利用数据和AI进行手术规划的Caresurgical/VELYS数字手术系统 [25][26] - 其Polyphonic数字生态系统连接手术室，允许外科医生与远程同行共享实时视频和数据，系统中的AI有助于识别手术视频中的重要事件以供讨论 [26] - 公司当前财年预期营收和盈利增长率分别为5%和5.7%，过去30天当前财年盈利的共识预期上调了0.1% [27] - 公司贝塔值为0.34，当前股息收益率为2.5%，净资产收益率为32.7% [27]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Novo Nordisk's Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said. ...

Jupiter, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR) today announced that it has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, Itonis’s over-the-counter (OTC) nausea relief product. The agreement provides Caring Brands with full rights to commercialize Emesyl and to oversee all manufacturing activities associated with the product. Under the terms of the agreement, Caring Brands will assume responsibility fo ...